Sodium-glucose cotransporter 2 inhibitors: A drug with antidiabetic and cardioprotective properties.
作者信息
Li Hung-Yuan
机构信息
Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
出版信息
J Diabetes Investig. 2021 Mar;12(3):310-312. doi: 10.1111/jdi.13413. Epub 2020 Oct 22.
Abstract
摘要
相似文献
1
Sodium-glucose cotransporter 2 inhibitors: A drug with antidiabetic and cardioprotective properties.
J Diabetes Investig. 2021 Mar;12(3):310-312. doi: 10.1111/jdi.13413. Epub 2020 Oct 22.
2
Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.
Nat Rev Endocrinol. 2020 Oct;16(10):556-577. doi: 10.1038/s41574-020-0392-2. Epub 2020 Aug 27.
3
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.
Am Heart J. 2021 Feb;232:116-124. doi: 10.1016/j.ahj.2020.10.071. Epub 2020 Nov 2.
4
Sodium-glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease.
ESC Heart Fail. 2022 Oct;9(5):3661-3662. doi: 10.1002/ehf2.14095. Epub 2022 Jul 25.
5
Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
Ann Pharmacother. 2021 Feb;55(2):252-260. doi: 10.1177/1060028020934001. Epub 2020 Jun 13.
6
The Off-Target Cardioprotective Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors: An Overview.
Int J Mol Sci. 2024 Jul 14;25(14):7711. doi: 10.3390/ijms25147711.
7
SGLT-2 inhibitors: Diabetes and CKD and CHF (and gout?), oh my!
Cleve Clin J Med. 2024 Jul 1;91(7):392-393. doi: 10.3949/ccjm.91b.07024.
8
Which person with diabetes should receive cardioprotective glucose-lowering medicines?
J Diabetes. 2020 May;12(5):352-353. doi: 10.1111/1753-0407.13029.
9
SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with One Stone?
Cardiology. 2020;145(5):311-320. doi: 10.1159/000504694. Epub 2019 Dec 20.
10
SGLT-2 inhibitors in heart failure and chronic kidney disease: A review for internists.
Cleve Clin J Med. 2024 Jul 1;91(7):415-423. doi: 10.3949/ccjm.91a.23093.
引用本文的文献
1
Cardiovascular disease in patients with type 2 diabetes.
J Diabetes Investig. 2022 Apr;13(4):614-616. doi: 10.1111/jdi.13742. Epub 2022 Jan 19.
2
COVID-19 and cardiovascular complications: an update from the underlying mechanism to consequences and possible clinical intervention.
Expert Rev Anti Infect Ther. 2021 Sep;19(9):1083-1092. doi: 10.1080/14787210.2021.1893692. Epub 2021 Mar 5.
本文引用的文献
1
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
2
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control.
Nat Rev Cardiol. 2020 Dec;17(12):761-772. doi: 10.1038/s41569-020-0406-8. Epub 2020 Jul 14.
3
Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence.
Prog Cardiovasc Dis. 2020 Sep-Oct;63(5):570-584. doi: 10.1016/j.pcad.2020.04.011. Epub 2020 May 5.
4
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
JAMA. 2020 Apr 14;323(14):1353-1368. doi: 10.1001/jama.2020.1906.
5
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
Zotero 插件